vs
Side-by-side financial comparison of Unum Group (UNM) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.
Unum Group is the larger business by last-quarter revenue ($3.4B vs $3.0B, roughly 1.1× Vertex Pharmaceuticals). Vertex Pharmaceuticals runs the higher net margin — 34.5% vs 6.9%, a 27.6% gap on every dollar of revenue. On growth, Unum Group posted the faster year-over-year revenue change (8.5% vs 7.8%). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (6.3% CAGR vs 1.9%).
Unum Group is an American insurance company headquartered in Chattanooga, Tennessee. Founded as Union Mutual in 1848 and known as UnumProvident from 1999–2007, the company is part of the Fortune 500. Unum Group was created by the 1999 merger of Unum Corporation and The Provident Companies and comprises four distinct businesses – Unum US, Unum UK, Unum Poland and Colonial Life. Its underwriting insurers include The Paul Revere Life Insurance Company and Provident Life and Accident Insurance Co...
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
UNM vs VRTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.4B | $3.0B |
| Net Profit | $232.0M | $1.0B |
| Gross Margin | — | 86.8% |
| Operating Margin | — | 38.1% |
| Net Margin | 6.9% | 34.5% |
| Revenue YoY | 8.5% | 7.8% |
| Net Profit YoY | 22.7% | 59.6% |
| EPS (diluted) | — | $4.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.4B | $3.0B | ||
| Q4 25 | $3.2B | $3.2B | ||
| Q3 25 | $3.4B | $3.1B | ||
| Q2 25 | $3.4B | $3.0B | ||
| Q1 25 | $3.1B | $2.8B | ||
| Q4 24 | $3.2B | $2.9B | ||
| Q3 24 | $3.2B | $2.8B | ||
| Q2 24 | $3.2B | $2.6B |
| Q1 26 | $232.0M | $1.0B | ||
| Q4 25 | $174.1M | $1.2B | ||
| Q3 25 | $39.7M | $1.1B | ||
| Q2 25 | $335.6M | $1.0B | ||
| Q1 25 | $189.1M | $646.3M | ||
| Q4 24 | $348.7M | $913.0M | ||
| Q3 24 | $645.7M | $1.0B | ||
| Q2 24 | $389.5M | $-3.6B |
| Q1 26 | — | 86.8% | ||
| Q4 25 | — | 85.4% | ||
| Q3 25 | — | 86.5% | ||
| Q2 25 | — | 86.3% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 85.5% | ||
| Q3 24 | — | 85.8% | ||
| Q2 24 | — | 85.9% |
| Q1 26 | — | 38.1% | ||
| Q4 25 | 6.7% | 37.8% | ||
| Q3 25 | 1.6% | 38.6% | ||
| Q2 25 | 12.4% | 38.8% | ||
| Q1 25 | 7.9% | 22.7% | ||
| Q4 24 | 13.8% | 35.2% | ||
| Q3 24 | 15.6% | 40.3% | ||
| Q2 24 | 15.3% | -132.9% |
| Q1 26 | 6.9% | 34.5% | ||
| Q4 25 | 5.4% | 37.3% | ||
| Q3 25 | 1.2% | 35.2% | ||
| Q2 25 | 10.0% | 34.8% | ||
| Q1 25 | 6.1% | 23.3% | ||
| Q4 24 | 10.8% | 31.4% | ||
| Q3 24 | 20.1% | 37.7% | ||
| Q2 24 | 12.0% | -135.8% |
| Q1 26 | — | $4.02 | ||
| Q4 25 | $1.06 | $4.64 | ||
| Q3 25 | $0.23 | $4.20 | ||
| Q2 25 | $1.92 | $3.99 | ||
| Q1 25 | $1.06 | $2.49 | ||
| Q4 24 | $1.91 | $3.62 | ||
| Q3 24 | $3.46 | $4.01 | ||
| Q2 24 | $2.05 | $-13.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | — |
| Total DebtLower is stronger | $3.8M | — |
| Stockholders' EquityBook value | $10.9M | $19.4B |
| Total Assets | $62.7M | $26.5B |
| Debt / EquityLower = less leverage | 0.35× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.1M | — | ||
| Q4 25 | — | $6.6B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $5.8B |
| Q1 26 | $3.8M | — | ||
| Q4 25 | $3.8B | — | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $3.5B | — | ||
| Q1 25 | $3.5B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.5B | — |
| Q1 26 | $10.9M | $19.4B | ||
| Q4 25 | $11.1B | $18.7B | ||
| Q3 25 | $10.9B | $17.3B | ||
| Q2 25 | $11.3B | $17.2B | ||
| Q1 25 | $11.2B | $16.5B | ||
| Q4 24 | $11.0B | $16.4B | ||
| Q3 24 | $11.0B | $15.6B | ||
| Q2 24 | $10.5B | $14.8B |
| Q1 26 | $62.7M | $26.5B | ||
| Q4 25 | $63.5B | $25.6B | ||
| Q3 25 | $63.7B | $24.9B | ||
| Q2 25 | $62.8B | $24.0B | ||
| Q1 25 | $62.5B | $22.9B | ||
| Q4 24 | $62.0B | $22.5B | ||
| Q3 24 | $64.1B | $22.2B | ||
| Q2 24 | $62.0B | $20.1B |
| Q1 26 | 0.35× | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.32× | — | ||
| Q2 25 | 0.31× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.33× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
UNM
| Premium Income | $2.8B | 83% |
| Other | $561.2M | 17% |
VRTX
| TRIKAFTA/KAFTRIO | $2.4B | 79% |
| ALYFTREK | $424.4M | 14% |
| Other | $135.9M | 5% |
| CASGEVY | $42.9M | 1% |
| Vertex recorded | $29.0M | 1% |
